March 29th, 2022 | 13:34 CEST
Valneva, Triumph Gold, BioNTech - Gold rush mood in the pipeline
Table of contents:
"[...] We have a clear strategy for neutralizing sovereign risk in Papua New Guinea. [...]" Matthew Salthouse, CEO, Kainantu Resources
Born in Bielefeld, she studied German, English and psychology. The emergence of the Internet in the early '90s led her from university to training in graphic design and marketing communications. After years of agency work in corporate branding, she switched to publishing and learned her editorial craft at Hubert Burda Media.
Valneva - Bahrain receives emergency approval for COVID-19 vaccine VLA2001
Valneva is also one of the COVID-19 vaccine producers. In contrast to the mRNA vaccines, the French-Austrian company relies on so-called dead vaccines. A dead vaccine contains killed pathogens. Once injected, the body recognizes these foreign pathogens and produces defensive substances to protect against possible disease outbreaks. mRNA vaccines, on the other hand, use the injected spike protein to ensure the body itself produces small portions of the pathogen.
Now Valneva has sent its first doses of the inactivated vaccine to Bahrain in the Middle East. The island nation above Qatar, with a population of nearly 1.7 million, was granted "emergency approval" for the VLA2001 vaccine in early March, making it the first country in the world to approve this COVID-19 vaccine. The supplier of the vaccine is Valneva's plant in Sweden.
In November 2021, Valneva signed an agreement with the European Commission to supply up to 60 million doses of VLA2001 over two years, including 24.3 million doses in 2022 and the remainder via options in 2023. Gold rushes come from long-term contracts with countries and a virus, which remains infectious with new mutants.
Triumph Gold - New occurrence of precious metal at the Yukon
Limited values like precious metals belong as an admixture in well-sorted portfolios. Classics such as gold and silver are suitable for risk-averse investors. Gold supply depends largely on the gold production from the corresponding mines. Gold mining shares offer an alternative to ETC or ETFs. One theory on the price of gold is that as the supply from the scrapings increases, so does the price of gold.
According to an overview by Statista, Australia and Russia have the world's largest gold mine reserves at 11,000 tons and 6,800 tons, respectively. The US and Canada are also countries with high levels of mineral resources. For example, Canada's Triumph Gold Corporation (TIGCF) owns an area on the legendary Yukon River. The Company specializes in the discovery and development of gold and other valuable raw material deposits such as copper and diamonds.
The Freegold Mountain gold-copper project is located in the Dawson Range, approximately 70km northwest of Carmacks, Yukon. Drilling on the area by Triumph Gold to date is promising. The more gold that is found, the higher the price of the share will go.
The Yukon region in northwestern Canada is a paradise for nature lovers. Majestic mountain ranges, crisscrossed by endless rivers, invite hikers to explore the area themselves on the signposted hiking wagons or to walk directly along the Gold Rush Trail. And if you pass by the Dawson Range, you may have already invested in Triumph Gold.
BioNTech - Exciting look towards quarterly figures
BioNTech's German headquarters are located in Mainz on Goldgrube - Gold Mine. The street name could be symbolic of the upcoming full-year and fourth-quarter 2021 results on March 30, for which you can register here for the webcast.
According to Reuters news agency, the German government plans to spend up to EUR 2.8 billion to secure production capacity for the COVID-19 vaccine. BioNTech is one of five partners with whom the German government is contracting. In addition to BioNTech, these include IDT, Celonic and the bidding consortia of CureVac/GSK and Wacker/Corden Pharma.
At the national level, German companies BioNTech, CureVac and IDT Biologika (IDT) received funding from a special program to accelerate research and development by the German Federal Ministry of Education and Research. In return, the federal government expects them to make a fair share of the production of an approved COVID-19 vaccine available for needs-based supply in Germany. BioNTech investors will know tomorrow at the latest to what extent vaccine production will be sufficient to remain on track for success. But BioNTech has more in the pipeline than just the COVID-19 vaccine. In addition to influenza, shingles and tuberculosis, the Company's pipeline is also well filled in the field of oncology.
If it were up to the current German Minister of Health, Lauterbach, the pandemic would probably never end. Measures in the federal states are once again being extended through the loophole of hotspot regulations to contain the virus without any concrete indication. However, there is still a lack of valid data as to when prime ministers are allowed to declare their federal state or cities within it a so-called corona hotspot. The decision is made purely based on a gut feeling. On April 2, the measures are finally to be abolished in Germany. In Spain, on the other hand, anyone who tests positive for Corona is allowed to leave their quarantine since yesterday, provided they are symptom-free. That means the country is now treating COVID-19 similarly to influenza.
Pharmaceutical and biotech companies are looking at long-term development pipelines and are subject to strict regulations until a new therapeutic makes a profit in the market. Current emergency approvals provide an exception, allowing both Valneva and BioNTech to bring their vaccines to market. In the case of BioNTech, contracts with governments secure the site in Mainz, Germany. Gold stocks such as Triumph Gold are performing similarly to the gold price. In the picturesque Yukon, the Company owns an area with gold, copper and diamond deposits. These will be mined in the future.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.
In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
For this reason, there is a concrete conflict of interest.
The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.